177 related articles for article (PubMed ID: 14871103)
1. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.
Shamis M; Lode HN; Shabat D
J Am Chem Soc; 2004 Feb; 126(6):1726-31. PubMed ID: 14871103
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry.
Gopin A; Ebner S; Attali B; Shabat D
Bioconjug Chem; 2006; 17(6):1432-40. PubMed ID: 17105221
[TBL] [Abstract][Full Text] [Related]
3. Remarkable drug-release enhancement with an elimination-based AB3 self-immolative dendritic amplifier.
Sagi A; Segal E; Satchi-Fainaro R; Shabat D
Bioorg Med Chem; 2007 Jun; 15(11):3720-7. PubMed ID: 17416532
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic activation of hydrophobic self-immolative dendrimers: the effect of reporters with ionizable functional groups.
Avital-Shmilovici M; Shabat D
Bioorg Med Chem Lett; 2009 Jul; 19(14):3959-62. PubMed ID: 19303773
[TBL] [Abstract][Full Text] [Related]
5. Design of self-immolative linkers for tumour-activated prodrug therapy.
Tranoy-Opalinski I; Fernandes A; Thomas M; Gesson JP; Papot S
Anticancer Agents Med Chem; 2008 Aug; 8(6):618-37. PubMed ID: 18690826
[TBL] [Abstract][Full Text] [Related]
6. A new visual screening assay for catalytic antibodies with retro-aldol retro-Michael activity.
Shamis M; Barbas CF; Shabat D
Bioorg Med Chem Lett; 2007 Mar; 17(5):1172-5. PubMed ID: 17234408
[TBL] [Abstract][Full Text] [Related]
7. Bioactivation of carbamate-based 20(S)-camptothecin prodrugs.
Pessah N; Reznik M; Shamis M; Yantiri F; Xin H; Bowdish K; Shomron N; Ast G; Shabat D
Bioorg Med Chem; 2004 Apr; 12(8):1859-66. PubMed ID: 15051055
[TBL] [Abstract][Full Text] [Related]
8. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
Gopin A; Pessah N; Shamis M; Rader C; Shabat D
Angew Chem Int Ed Engl; 2003 Jan; 42(3):327-32. PubMed ID: 12548691
[No Abstract] [Full Text] [Related]
9. In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy.
Shabat D; Lode HN; Pertl U; Reisfeld RA; Rader C; Lerner RA; Barbas CF
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7528-33. PubMed ID: 11404472
[TBL] [Abstract][Full Text] [Related]
10. Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy.
Sinha SC; Li LS; Watanabe S; Kaltgrad E; Tanaka F; Rader C; Lerner RA; Barbas CF
Chemistry; 2004 Oct; 10(21):5467-72. PubMed ID: 15378729
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Abraham S; Guo F; Li LS; Rader C; Liu C; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5584-9. PubMed ID: 17372220
[TBL] [Abstract][Full Text] [Related]
12. Receiver-amplifier, self-immolative dendritic device.
Amir RJ; Danieli E; Shabat D
Chemistry; 2007; 13(3):812-21. PubMed ID: 17075925
[TBL] [Abstract][Full Text] [Related]
13. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
14. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
15. Self-immolative anthracycline prodrugs for suicide gene therapy.
Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
[TBL] [Abstract][Full Text] [Related]
16. A self-immolative prodrug nanosystem capable of releasing a drug and a NIR reporter for in vivo imaging and therapy.
Wang Z; Wu H; Liu P; Zeng F; Wu S
Biomaterials; 2017 Sep; 139():139-150. PubMed ID: 28614754
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and assessment of first-generation polyamidoamine dendrimer prodrugs to enhance the cellular permeability of P-gp substrates.
Najlah M; Freeman S; Attwood D; D'Emanuele A
Bioconjug Chem; 2007; 18(3):937-46. PubMed ID: 17355118
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and characterization of a catalytic antibody-HPMA copolymer-Conjugate as a tool for tumor selective prodrug activation.
Satchi-Fainaro R; Wrasidlo W; Lode HN; Shabat D
Bioorg Med Chem; 2002 Sep; 10(9):3023-9. PubMed ID: 12110325
[TBL] [Abstract][Full Text] [Related]
19. Development of self-immolative dendrimers for drug delivery and sensing.
Wang RE; Costanza F; Niu Y; Wu H; Hu Y; Hang W; Sun Y; Cai J
J Control Release; 2012 Apr; 159(2):154-63. PubMed ID: 22155555
[TBL] [Abstract][Full Text] [Related]
20. A doxorubicin prodrug activated by the staudinger reaction.
van Brakel R; Vulders RC; Bokdam RJ; Grüll H; Robillard MS
Bioconjug Chem; 2008 Mar; 19(3):714-8. PubMed ID: 18271515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
